Evidence map›Paper›PMID 42373988›Full record

ArticleNature immunology2026

Editorial Expression of Concern: Recognition of the nonclassical MHC class I molecule H2-M3 by the receptor Ly49A regulates the licensing and activation of NK cells.

Daniel M Andrews, Lucy C Sullivan, Nikola Baschuk, Christopher J Chan, Richard Berry, Claire L Cotterell, Jie Lin, Heloise Halse, Sally V Watt, Jennifer Poursine-Laurent and 6 more

Abstract readExpression of Concern
PubMed Publisher
In one paragraph

Article in Nature immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

16 authors.

Daniel M AndrewsCancer Immunology Program, Trescowthick Laboratories, Peter MacCallum Cancer Centre, St. Andrews Place, East Melbourne, Australia. daniel.andrews@petermac.org.
Lucy C Sullivan *Department of Microbiology and Immunology, University of Melbourne, Parkville, Australia.
Nikola Baschuk *Cancer Immunology Program, Trescowthick Laboratories, Peter MacCallum Cancer Centre, St. Andrews Place, East Melbourne, Australia.
Christopher J ChanCancer Immunology Program, Trescowthick Laboratories, Peter MacCallum Cancer Centre, St. Andrews Place, East Melbourne, Australia.
Richard BerryDepartment of Biochemistry and Molecular Biology, School of Biomedical Sciences, Monash University, Clayton, Australia.
Claire L CotterellCancer Immunology Program, Trescowthick Laboratories, Peter MacCallum Cancer Centre, St. Andrews Place, East Melbourne, Australia.
Jie LinDepartment of Microbiology and Immunology, University of Melbourne, Parkville, Australia.
Heloise HalseCancer Immunology Program, Trescowthick Laboratories, Peter MacCallum Cancer Centre, St. Andrews Place, East Melbourne, Australia.
Sally V WattCancer Immunology Program, Trescowthick Laboratories, Peter MacCallum Cancer Centre, St. Andrews Place, East Melbourne, Australia.
Jennifer Poursine-LaurentRheumatology Division, Department of Medicine, Washington University School of Medicine, St. Louis, Missouri, USA.
Chyung-Ru WangDepartment of Microbiology and Immunology, Northwestern University, Chicago, Illinois, USA.
Anthony A ScalzoCentre for Ophthalmology and Vision Science, University of Western Australia, Crawley, Australia.
Wayne M YokoyamaRheumatology Division, Department of Medicine, Washington University School of Medicine, St. Louis, Missouri, USA.
Jamie RossjohnDepartment of Biochemistry and Molecular Biology, School of Biomedical Sciences, Monash University, Clayton, Australia.
Andrew G Brooks *Department of Microbiology and Immunology, University of Melbourne, Parkville, Australia.
Mark J Smyth *Cancer Immunology Program, Trescowthick Laboratories, Peter MacCallum Cancer Centre, St. Andrews Place, East Melbourne, Australia. mark.smyth@petermac.org.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID42373988

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.